brentuximab vedotin
seagen,takeda
['lymsm']
echelon-1 os update
#asco22 #lymsm n=1334
6y os 93.9 vs 89.4% hr 0.59
6y pfs 82.3 vs 74.5%
so overall 8% pfs and 4% os benefit. curious about everyone's thoughts.
i'm thinking aavd for pts&lt;60 as 1st choice? 
Clinician-researcher-educator bookworm @RoswellPark. Passionate about #Lymphoma #CLL #GeriOnc #PRO #MedEd Proud alum @OfficialJipmer @AIIMS_ND @UpstateNews